ReviewJournal of hepatology2020
Advances in functional and molecular MRI technologies in chronic liver diseases.
Review in Journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Application of Magnetic Resonance Imaging in Liver Biomechanics: A Systematic Review.Frontiers in physiology · 2021Pooled it
- MRI-Derived Evaluation of Liver Function and Its Extension to K-Edge Photon-Counting CT: Focus on Gadolinium-Based Functional Biliary Imaging.Diagnostics (Basel, Switzerland) · 2026Review
- Gadoxetic Acid-Enhanced T1 Mapping Enables Transporter-Mediated Molecular Imaging of Liver Functional Reserve.Biomedicines · 2026Article
- From targeted delivery to inflammation suppression: engineering plant exosomes for heart failure therapy post-infarction.Materials today. Bio · 2026Article
- Inflammatory and resolution stages of hepatic injury: imaging with USPIO-enhanced MRI in mice.European radiology experimental · 2026Article
- Mechanisms of Action and Biomarker Potential of ncRNAs in Hepatocellular Carcinoma and Liver Fibrosis: A Review.Analytical cellular pathology (Amsterdam) · 2026Review
- Article
- Article
- Diagnostic performances of adding transition and hepatobiliary phase to washout in gadoxetic acid-enhanced MRI for subcentimeter hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Generation of a High-Precision Whole Liver Panorama and Cross-Scale 3D Pathological Analysis for Hepatic Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma: nomograms based on deep learning analysis of gadoxetic acid-enhanced MRI.European radiology · 2025Article
- The value of contrast-enhanced ultrasound fusion imaging in percutaneous liver biopsy for liver lesions invisible on conventional B-mode ultrasound.Quantitative imaging in medicine and surgery · 2025Article
- Type I collagen-targeted liposome delivery of Serca2a modulates myocardium calcium homeostasis and reduces cardiac fibrosis induced by myocardial infarction.Materials today. Bio · 2024Article
- Endotoxin Detection in Magnetic Resonance Imaging Contrast Agent Using Optimising Chromogenic Limulus Amebocyte Lysate Assay.The Malaysian journal of medical sciences : MJMS · 2024Article
- Whole-liver histogram analysis of hepatocyte-specific contrast-enhanced magnetic resonance imaging for predicting progression in patients with cirrhosis.Quantitative imaging in medicine and surgery · 2024Article
- Construction of Targeting-Peptide-Based Imaging Reagents and Their Application in Bioimaging.Chemical & biomedical imaging · 2024Review
- Usefulness of Diffusion-Weighted Imaging in Evaluating Acute Cellular Rejection and Monitoring Treatment Response in Liver Transplant Recipients.Diagnostics (Basel, Switzerland) · 2024Article
- Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.Theranostics · 2024Review
- Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis.Biomaterials research · 2024Review
- Application of Pharmacokinetic Modeling to Characterize Hepatobiliary Disposition of Imaging Agents and Alterations due to Liver Injury in Isolated Perfused Rat Livers.Pharmaceutical research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
MRI has emerged as the most comprehensive non-invasive diagnostic tool for liver diseases. In recent years, the value of MRI in hepatology has been significantly enhanced by a wide range of contrast agents, both clinically available and under development, that add functional information to anatomically detailed morphological images, or increase the distinction between normal and pathological tissues by targeting molecular and cellular events. Several classes of contrast agents are available for contrast-enhanced hepatic MRI, including i) conventional non-specific extracellular fluid contrast agents for assessing tissue perfusion; ii) hepatobiliary-specific contrast agents that are taken up by functioning hepatocytes and excreted through the biliary system for evaluating hepatobiliary function; iii) superparamagnetic iron oxide particles that accumulate in Kupffer cells; and iv) novel molecular contrast agents that are biochemically targeted to specific molecular/cellular processes for staging liver diseases or detecting treatment responses. The use of different functional and molecular MRI methods enables the non-invasive assessment of disease burden, progression, and treatment response in a variety of liver diseases. A high diagnostic performance can be achieved with MRI by combining imaging biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.